Peptide Mimics as Potential Drugs for COVID-19
Shimon Shatzmiller*, Rami Krieger, Galina zats & Inbal Lapidot
Department of Chemical Sciences, Ariel University, Ariel 40700, Israel
Dr. Shimon Shatzmiller, Lecturer, University of Medicine, Tirana, Albania.
Keywords: Omicron; Antibodies; COVID-19
It seems to me that the omicron, with all its monstrosity, is just a trailer for what is yet to come in the next stage. The problem focuses on the antibodies that the body produces, making it difficult for the virus to transfer its genetic material to "kidnapping" the various intracellular mechanisms to produce a host in the host cells the RNA and proteins of the virus. The transition has hitherto been the most common receptor in all of our body cells ACE2-. The protein of the antibodies acts as a mechanical inhibitor (SPIKE) of the virus in binding to the receptor. And like many good things, this way of stopping will at some point come to a dead end.
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).